XML 233 R49.htm IDEA: XBRL DOCUMENT
v3.26.1

Net Loss Per Share (Tables) | 9 Months Ended | 12 Months Ended
--- | --- | ---
Feb. 28, 2026 | Dec. 31, 2025 | May 31, 2025
Net Loss Per Share (Tables) [Line Items] |  |  |
Schedule of Basic and Diluted Loss Per Share |  | The following table sets forth the computation of basic and diluted loss per share:
|  | Year ended December 31, 2025 |  | Year ended December 31, 2024 |  | Year ended December 31, 2023
Numerator: |  |  |  |  |  |  |  |  |  |  |
Net loss attributable to Aptorum Group Limited |  | $ | (1,363,270 | ) |  | $ | (4,267,806 | ) |  | (2,824,647 | )
Denominator: |  |  |  |  |  |  |  |  |  |  |
Basic and diluted weighted average shares outstanding |  |  | 7,351,784 |  |  |  | 5,453,103 |  |  | 4,521,133 |
Net loss per share attributable to Aptorum Group Limited(1) |  |  |  |  |  |  |  |  |  |  |
Basic and diluted loss per share |  | $ | (0.19 | ) |  | $ | (0.78 | ) |  | (0.62 | )
DiamiR Biosciences Corp. [Member] |  |  |
Net Loss Per Share (Tables) [Line Items] |  |  |
Schedule of Antidilutive Common Stock Equivalents | The following common stock equivalents have been excluded from the calculation of loss per share because their effects would be antidilutive in the nine months ended February 28:
|  | 2026 |  | 2025
Stock options |  | 441,750 |  | 511,950
Restricted stock |  | 88,000 |  | 88,000
Warrants |  | — |  | 29,336
|  | The following common stock equivalents have been excluded from the calculation of loss per share because their effects would be antidilutive:
|  | 2025 |  | 2024
Stock options |  | 511,950 |  | 511,950
Restricted stock |  | 88,000 |  | 88,000
Warrants |  | — |  | 29,336

X
- References No definition available. + Details
Name: | apm_NetLossPerShareTablesLineItems
Namespace Prefix: | apm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=apm_DiamiRBiosciencesCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |